Abstract
Five-lipoxygenase (5-LOX) inhibition is gaining increasing importance as a novel approach to therapy of allergic asthma and other inflammatory diseases. Presently, two types of inhibitors are known, direct 5-LOX inhibitors (LOI) and the FLAP (five lipoxygenase activating protein) binding leukotriene synthesis inhibitors (LSI). The 5-LOX selective and orally active quinoline LSI, BAY X 1005, shares many mechanistic features with the indole LSI, MK-886. The binding of BAY X 1005 to FLAP correlates with LTB4 synthesis inhibition. BAY X 1005 has been shown to bind to the 18 kD protein FLAP. BAY X 1005 inhibits 5-LOX translocation from the cytosol to membranes and reverses 5-LOX translocation. The use of BAY X 1005 has helped to elucidate part of the complex FLAP/5-LOX interaction by showing that FLAP appears to represent a 5-LOX substrate transfer protein channelling endogenous and exogenous arachidonic acid to the leukotriene synthetizing 5-LOX. This notion presented by our group in 1992 has stimulated further mechanistic studies. These findings have additionally led to the hypothesis that substrate competition is not confined to the LSI/FLAP interaction but may also be true for the LOI/5-LOX interaction and that even mixed LSI/LOI 5-LOX inhibitors are feasible, yet have not been described. Further mechanistic work on LSI will be orientated not only to further elucidate the complex FLAP/5-LOX interaction, but also to identify FLAP-related eicosanoid binding proteins.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
J. Y. Vanderhoek, R. W. Bryant, and J. M. Bailey,Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid. J. Biol. Chem.255, 10064–10066 (1980).
S. M. Coutts, A. Khandwala, R. van Inwegen, U. Chakraborty, J. Musser, J. Bruens, N. Jariwala, V. Dally-Meade, R. Ingram, T. Pruss, H. Jones, E. Neiss, and I. Weinryb,Arymethyl phenyl ethers. A new class of specific inhibitors of 5-lipoxygenase. InProstaglandins, Leukotrienes and Lipoxins. Biochemistry, Mechanism of Action, and Clinical Applications. (Ed. J. M. Bailey) pp. 627–637. Plenum Press, New York, 1985.
R. Müller-Peddinghaus, R. Fruchtmann, H.-J., Ahr, B. Beckermann, K. Bühner, B. Fugmann, B. Junge, M. Matzke, C. Kohlsdorfer, S. Raddatz, P. Theisen-Popp and K.-H. Mohrs,BAY X 1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics. J. Lipid Mediators6, 245–248 (1993).
R. Müller-Peddinghaus, C. Kohlsdorfer, P. Theisen-Popp, R. Fruchtmann, E. Perzborn, B. Beckerman, K. Bühner, H.-J. Ahr and K.-H. Mohrs,BAY X 1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J. Pharmacol. Exp. Therap.,267, 51–57 (1993).
I. Gorenne, C. Labat, J. P. Gascard, X. Norel, R. Müller-Peddinghaus, K. H. Mohrs, W. A. Taylor, P. J. Gardiner, and C. Brink,(R)-2-[4-(quinolin-2-yl-methoxy) phenyl]-2-cyclopentyl] acetic acid (BAY X 1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J. Pharmacol. Exp. Therap.,268, 868–872 (1993).
P. J. Gardiner, N. J. Cuthbert, H. P. Francis, M. F. Fitzgerald, A. M. Thompson, T. G. Carpenter, U. P. Patel, B. B. Newton, K. Mohrs, R. Müller-Peddinghaus, W. A. Taylor,Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY X 1005. Eur. J. Pharmacol,258, 95–102 (1994).
R. Fruchtmann, K.-H. Mohrs, A. Hatzelmann, S. Raddatz, B. Fugmann, B. Junge, H. Horstmann and R. Müller-Peddinghaus,In vitro pharmacology of BAY X 1005, a new inhibitor of leukotriene synthesis. Agents Actions,38, 188–195 (1993).
A. Hatzelmann, R. Fruchtmann, K. H. Mohrs, S. Raddatz and R. Müller-Peddinghaus,Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 {(R)-2-[4-(quinolin-2-yl-methoxy) phenyl]-2-cyclopentyl acetic acid} and structurally related compounds Biochem. Pharmacol,45, 101–111 (1993).
A. Hatzelmann, R. Fruchtmann, K.-H. Mohrs, S. Raddatz and R. Müller-Peddinghaus,The Ca 2+ ionophore A13187-stimulated secretion of azurophil granules in human polymorphonuclear leukocytes is largely mediated by endogenously formed leukotriene B 4 Biochem. Pharmacol.48, 31–39 (1994).
J. Gillard, A. W. Ford-Hutchinson, C. Chan, S. Charleson, D. Denis, A. Foster, R. Fortin, S. Leger, C. S. McFarlane, H. Morton, H. Piechuta, D. Riendeau, C. A. Rouzer, J. Rokach, and R. Young,L-663, 536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Pysiol. Pharmacol.67, 456–464 (1989).
D. K. Miller, J. W. Gillard, P. J. Vickers, S. Sadowski, C. Léveillé, J. A. Mancini, P. Charleson, R. A. F. Dixon, A. W. Ford-Hutchinson, R. Fortin, J. Y. Gauthier, J. Rodkey, R. Rosen, C. Rouzer, I. S. Sigal, C. D. Strader and J. F. Evans,Identification and isolation of a membrane protein necessary for leukotriene production. Nature (London),343, 278–281 (1990).
R. A. F. Dixon, R. E. Diehl, E. Opas, E. Rands, P. J. Vickers, J. F. Evans, J. W. Gillard and D. K. Miller,Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature (London)343, 282–284 (1990).
J. F. Evans, C. Leveillé, J. A. Mancini, P. Prasit, M. Thérien, R. Zamboni, J. Y. Gauthier, R. Fortin, P. Charleson, D. E. Macintyre, S. Luell, T. J. Bach, R. Meurer, J. Guay, P. J. Vickers, C. A. Rouzer, J. W. Gillard, and D. K. Miller,5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol. Pharmacol.40, 22–27 (1991).
R. Müller-Peddinghaus, R. Kast, A. Hatzelmann, R. Fruchtmann, P. J. Gardiner,BAY X 1005: pharmacology of leukotriene biosynthesis inhibition. Advances in understanding and treatment of asthma and COPD. Workshop held December 1–2, 1993, Key West, Florida, U.S.A. In press (1995).
A. W. Ford-Hutchinson,FLAP: a novel drug target for inhibiting the synthesis of leukotrienes. Trends Pharmacol. Sci.12, 68–70 (1991).
B. K. Lam, J. F. Penrose, G. J. Freeman, and K. F. Austen,Expression cloning of a cDNA for human leukotriene C synthase, an integral membrane protein conjugating reduce glutathione to leukotriene A 4. Proc. Natl. Acad. Sci. U.S.A.91 7663–7667 (1994).
A. Hatzelmann, J. Goossens, R. Fruchtmann, K.-H. Mohrs, S. Raddatz, and R. Müller-Peddinghaus,Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X 1005 and other quinoline derivatives in intact cells and a cell-free system-implications for the function of 5-lipoxygenase activating protein. Biochem. Pharmacol.47, 2259–2268 (1994).
C. A. Rouzer and S. Kargman,Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J. Biol. Chem.,263, 10980–10988 (1988).
C. A. Rouzer, A. W. Ford-Hutchinson, H. E. Morton, and J. W. Gillard,MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J. Biol. Chem.,265, 1436–1442 (1990).
S. Kargmann, P. Prasit, J. F. Evans,Translocation of HL-60 cell 5-lipoxygenase. Inhibition of A23187- or N-formyl-methionyl-leucyl-phenyllamine-induced translocation by indole and quinoline leukotriene synthesis inhibitors. J. Biol. Chem.266, 23745–23752 (1991).
S. Kargmann, P. J. Vickers, and J. F. Evans,A23187-induced translocation of 5-lipoxygenase in osteosarcoma cells. J. Cell Biol.,119, 1701–1709 (1992).
M. Coffey, M. Peters-Golden, J. C. Fantone, III, and P. H. S. Sporn,Membrane association of active 5-lipoxygenase in resting cells. Evidence for novel regulation of the enzyme in the rat alveolar macrophages. J. Biological Chem.267, 570–276 (1992).
R. Kast, R. Fruchtmann, R. Kupferschmidt, K. H. Mohrs, S. Raddatz, R. Müller-Peddinghaus, and A. Hatzelmann,Role of 5-lipoxygenase-activating protein in the regulation of 5-lipoxygenase activity in human neutrophils. Agents Actions41. C166-C168 (1994).
S. Charleson, J. F. Evans, S. Leger, H. Perrier, P. Prasit, W. Zy, P. J. Vickers,Structural requirements for the binding of fatty-acids to 5-lipoxygenase-activating protein. Eur. J. Pharmacol.-Mol. Pharmacol.,267, 275–280 (1994).
J. A. Mancini, M. Abramovitz, M. E. Cox, E. Wong, S. Charleson, H. Perrier, Z. Wang, P. Prasit and P. J. Vickers,5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett.318, 277–281 (1993).
M. Abramowitz, E. Wong, M. E. Cox, C. D. Richardson, C. Li and P. J. Vickers,5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur. J. Biochem.215, 105–111 (1993).
J. W. Woods, J. F. Evans, D. Ethier, S. Scott, P. J. Vickers, L. Hearn, J. A. Heibein, S. Charleson and I. I. Singer,5-lipoxygenase and 5-lipoxygenase-activating protein are localize in the nuclear envelope of activated human leukocytes. J. Exp. Med.178, 1935–1946 (1993).
M. Peters-Golden and R. W. McNish,Redistribution of 5-lipoxygenase and cytosolic phospholipase A 2 to the nuclear fraction upon macrophage activation. Biochem. Biophys. Res. Comm.196, 147–153 (1993).
M. K. Regier, D. L. DeWill, M. S. Schindler, and W. L. Smith,Subcellular localization of prostaglandin endoperoxide synthase-2 in murine 3T3 cells. Arch. Biochem. Biophys.301, 439–444 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hatzelmann, A., Fruchtmann, R., Mohrs, K.H. et al. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: Implications for biological regulation of 5-lipoxygenase. Agents and Actions 43, 64–68 (1994). https://doi.org/10.1007/BF02005767
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02005767